Literature DB >> 2060546

Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines.

K Häussermann1, B Benz, V Gekeler, K Schumacher, M Eichelbaum.   

Abstract

Verapamil, a calcium channel blocker, is used as the racemate. Recently, racemic verapamil has been shown to increase the cytotoxicity of vinca alkaloid and anthracycline derivatives in several resistant tumour cell lines. With respect to its cardiovascular activity S-verapamil is an order of magnitude more potent than R-verapamil. Since it was not known whether the effect on multi-drug resistance was also enantioselective a comparison has been made of the potency of the R and S enantiomers and racemic verapamil in their ability to increase the cytotoxicity of vincristine and daunomycin in sensitive (MOLT 4B) and drug resistant human T-lymphoma cell lines (MOLT/VCR-5 x 9, MOLT/DAU-8 and VCR 1000, a highly resistant subline of CCRF-CEM). Two major metabolites, norverapamil and D617 were tested in the same system. (+)-R, (-)-S-, racemic verapamil, norverapamil and D617 alone had no effect on cell growth in sensitive or resistant cell lines in concentrations up to 20 microM. In combination with vincristine, verapamil and norverapamil but not D617 produced a concentration dependent increase in the sensitivity of the resistant lines. Racemic verapamil, its individual enantiomers and norverapamil were equipotent. The concentration of the modifiers required to elicit 50% of the maximum effect (EC50) was of the order of 0.5 microM. No significant difference in the slopes of the concentration-effect curves were observed. The effect of verapamil and norverapamil was additive. In the sensitive MOLT 4B cell line both enantiomers and norverapamil increased sensitivity towards vincristine. However, the EC50 values were at least an order of magnitude higher (2.5-8 microM) than in the resistant cell lines.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060546     DOI: 10.1007/bf00315139

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Stereoselective protein binding of verapamil enantiomers.

Authors:  A S Gross; B Heuer; M Eichelbaum
Journal:  Biochem Pharmacol       Date:  1988-12-15       Impact factor: 5.858

2.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

3.  Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane.

Authors:  G Fairbanks; T L Steck; D F Wallach
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

4.  Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells.

Authors:  A Kimmig; V Gekeler; M Neumann; G Frese; R Handgretinger; G Kardos; H Diddens; D Niethammer
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

5.  Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors.

Authors:  M S Cairo; S Siegel; N Anas; L Sender
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

6.  Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro.

Authors:  E M Gibby; O Boyse; B T Hill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Phase I study of vinblastine and verapamil given by concurrent iv infusion.

Authors:  A B Benson; D L Trump; J M Koeller; M I Egorin; E A Olman; R S Witte; T E Davis; D C Tormey
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

8.  Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism.

Authors:  H Echizen; B Vogelgesang; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

9.  The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans.

Authors:  H Echizen; T Brecht; S Niedergesäss; B Vogelgesang; M Eichelbaum
Journal:  Am Heart J       Date:  1985-02       Impact factor: 4.749

10.  The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific.

Authors:  J A Plumb; R Milroy; S B Kaye
Journal:  Biochem Pharmacol       Date:  1990-02-15       Impact factor: 5.858

View more
  9 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.

Authors:  G H Mickisch; M A Noordzij; A vd Gaast; P Gebreamlack; K U Köhrmann; E Mogler-Drautz; H Kupper; F H Schröder
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 4.  Cellular drug efflux and reversal therapy of cancer.

Authors:  P W Wigler
Journal:  J Bioenerg Biomembr       Date:  1996-06       Impact factor: 2.945

5.  Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines.

Authors:  E Roller; B Klumpp; J Krause; M Eichelbaum; K Schumacher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Authors:  Monette M Cotreau; Lisa L von Moltke; David J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.

Authors:  K Mross; K Hamm; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Jejunal absorption and metabolism of R/S-verapamil in humans.

Authors:  R Sandström; A Karlsson; L Knutson; H Lennernäs
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

9.  ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.

Authors:  Cheol-Hee Choi
Journal:  Cancer Cell Int       Date:  2005-10-04       Impact factor: 5.722

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.